- Catalogue N°
- 855.980.000 - 200µg / 200µl
855.980.005 - 500µg / 500µl
- Target species
- Recognises both natural and recombinant human IL-34
- Myeloma X63/AG.8653 x Balb/c node cells
- Recombinant human IL-34
- 200µg or 500µg (Discovery Size also available please enquire)
- Mouse IgG1 Kappa light chain
- Phosphate-buffered saline. Sterile-filtered through 0.22 µm. Carrier and preservative free
- Stable at +2-8°C for 12 months. For longer storage freeze aliquots.
- Protein C16orf77
IL-34 has been first described in 2008 as a cytokine that plays a role in macrophage differentiation and proliferation.
The IL-34 protein is composed of 241 amino acids, with a molecular mass of 39 kDa, secreted as homodimer. Human IL-34 is 71% identical to mouse IL-34 on the amino acid level.
This cytokine shares numerous common features with macrophage colony-stimulating factor (M-CSF), especially its receptor, partly explaining their functional overlap. It is expressed in various tissues and it is most abundant in the spleen.It acts on tissue resident macrophages and Langerhans cells upon binding the receptor for CSF-1, CSF-1R.
Similar to M-CSF, IL-34 plays a major role in osteoclast genesis: in the presence of RANKL, IL-34 induces the proliferation and adhesion of osteoclast progenitors in vitro.
IL-34 has been implicated in some disease processes. For example, the role for IL-34 in rheumatoid arthritis (RA) has been evaluated. Joint fluid levels of IL-34 are increased in RA patients compared to controls with osteoarthritis. IL-34 expression levels in synovial membrane and joint fluid correlate with inflammation severity. In vitro, in the presence of TNF (and to a lesser degree of IL-1b or IL-17), rheumatoid synoviocytes produce IL-34 (whereas synoviocytes from osteoarthritic joints do not). Serum IL-34 levels are elevated in patients with RA.
Version 5 - 06.19
For research use only
For any order, the purchaser acknowledges having read and accepted the terms and conditions described on the Diaclone website.